NCT04645602View on ClinicalTrials.gov

Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papillomatosis Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Human Papilloma VirusRecurrent Respiratory PapillomatosisPulmonary Disease

Interventions

DRUG

Lenvatinib

Pill taken by mouth, once daily.

DRUG

Pembrolizumab

Intravenous injection through a vein (IV).

Trial Locations (1)

06510

RECRUITING

Yale University, New Haven

All Listed Sponsors

collaborator

Eisai Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Yale University

OTHER

NCT04645602 - Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papillomatosis Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement | Biotech Hunter | Biotech Hunter